Results 51 to 60 of about 642,659 (199)

The E3 ubiquitin ligase c-IAP1 regulates PCSK9-mediated LDLR degradation: Linking the TNF-α pathway to cholesterol uptake [PDF]

, 2010
Proprotein convertase subtilisin/kexin type 9 (PCSK9), in addition to LDLR (low-density lipoprotein receptor) and APOB (apolipoprotein B), is one of three loci implicated in autosomal dominant hypercholesterolaemia (ADH)^1^.
Lizhi Liu, Weiming Xu
core  

PCSK9 Activity Is Potentiated Through HDL Binding [PDF]

, 2021
RationaleProprotein convertase subtilisin/kexin type 9 (PCSK9) circulates in a free and lipoprotein-bound form, yet the functional consequence of the association between PCSK9 and high-density lipoprotein (HDL) remains unexplored.ObjectiveThis study ...
Bodo Levkau, Kiechl, Stefan, Theofilatos, Konstantinos, Levkau, Bodo, Wendy L. Hall, Notdurfter, Marlene, Marlene Notdurfter, Sarah E. Berry, Ruifang Lu, Paulweber, Bernhard, Hall, Wendy L, Sean A. Burnap, Gerd Heusch, Pechlaner, Raimund, Heusch, Gerd, Mayr, Manuel, Carlos Fernández-Hernando, Kaloyan Takov, Katherine Sattler, Konstantinos Theofilatos, Gregorio Rungger, Fernández-Hernando, Carlos, Willeit, Johann, Burnap, Sean A, Sattler, Katherine, Elisa Duregotti, Takov, Kaloyan, Sotirios Tsimikas, Lu, Ruifang, Takov, Kaloyan; id_orcid, Mayr, Manuel; id_orcid, Duregotti, Elisa, Stefan Kiechl, Tsimikas, Sotirios, Bernhard Paulweber, Raimund Pechlaner, Johann Willeit, Berry, Sarah E, Manuel Mayr, Rungger, Gregorio, Hall, Wendy Louise; id_orcid   +40 more
core   +1 more source

Insights into Binding Mechanisms of Potential Inhibitors Targeting PCSK9 Protein via Molecular Dynamics Simulation and Free Energy Calculation

Molecules
The design of small-molecule inhibitors targeting proprotein convertase subtilisin/Kein type 9 (PCSK9) remains a forefront challenge in combating atherosclerosis.
Xingyu Wu, Xi Zhu, Min Fang, Fenghua Qi, Zhixiang Yin, John Z.H. Zhang, Shihua Luo, Tong Zhu, Ya Gao   +8 more
doaj   +1 more source

Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis

Advanced Science, EarlyView.
Self‑amplifying PCSK9–LOX‑1 feedback axis drives atherosclerotic progression by promoting oxLDL generation and endothelial uptake. A dual‑targeting nanoplatform (siPCSK9@PEAL NPs‑aL) is constructed to simultaneously silence hepatic PCSK9 for lipid lowering and block plaque LOX‑1 for anti‑inflammation.
Yi Duan, Yijie Qiu, Yan Zhu, Quan Wang, Jiangtao Lin, Yourong Duan, Qi Wang, Yi Dong   +7 more
wiley   +1 more source

Relative change of LDL cholesterol after PCSK9 inhibitor therapy.

, 2019
Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be seen, the LDL cholesterol levels of individual patients (X-axis) ranged between +26% and -66% when comparing LDL levels after PCSK9 inhibitor therapy to ...
Alaeldin Addas (6236810), Gerhard Hindricks (52344), Michael Borger (5003072), Michael Kühl (132789), Christian Binner (6236801), Joanna Jozwiak (6236804), Boris Dinov (6236813), Julia Fischer (173836), Jochen Hahn (6236807), Jens Garbade (6236816)   +9 more
core   +1 more source

Dual‐Organelle Secretome Conjugation and Organ‐Uptake Tracking (DuO‐SCOUT) Enables Deep and Sensitive Mapping of the Secreted Proteins

Advanced Science, EarlyView.
A novel dual‐organelle proximity labeling platform, DuO‐SCOUT, decodes the complex landscape of systemic organ‐organ communication by capturing both classical and unconventional secretomes. Application in metabolic models maps the adipose‐to‐brain secretory relay, identifying selective extra‐hypothalamic sites for adipose‐derived factors and expanding ...
Fenglian Yang, Rui Qian, Jiaxing Song, Xingqi Meng, Jin Young Kim, Kwok On Lai, Li Wang, Liang Zhang   +7 more
wiley   +1 more source

Metabolic Memory in Cardiovascular Disease: Encoding, Propagation, and Therapeutic Targeting

Advanced Science, EarlyView.
Cardiovascular risk often persists after metabolic abnormalities are corrected. This conceptual Review frames such persistence as metabolic memory, encoded through a narrowing therapeutic window from reversible marks to irreversible damage, with continuous input from peripheral organs.
Cheng Cheng, Minghui Tang, Zhaobo Zhang, Ruoyi Qu, Jianfei Pei, Tian Liu, Siyao Qu, Shilong You, Shenshen Cui, Wenke Wang, Rui Zhao, Yingxian Sun, Naijin Zhang   +12 more
wiley   +1 more source

Phase Separation of TRIM21 Modulates PTPN14 Stability to Drive Flow‐Dependent Endothelial Activation and Atherogenesis

Advanced Science, EarlyView.
Disturbed flow promotes the formation of TRIM21‐rich biomolecular droplets, which concentrate TRIM21 and PTPN14 and facilitate their SPRY‐FERM interaction (illustrated by the TRIM21 D355‐PTPN14 R132 salt bridge). This condensate‐driven proximity enables TRIM21 to catalyze K48‐linked polyubiquitination of PTPN14 at lysine 956, leading to proteasome ...
Xue He, Qiannan Ma, Xue Wang, Jiaxu Mang, Chufeng Li, Bingjun Wu, Liu Yao, Yequn Chen, Qiankun Bao, Yi Zhu, Jinlong He   +10 more
wiley   +1 more source

PCSK9 Inhibition could be Effective for Acute Myocardial Infarction.

, 2022
In this review, we explore the role of PCSK9 and the inhibition of PCSK9 in patients after acute myocardial infarction (MI). Despite the implementation of evidencebased therapies to improve outcomes, one-year mortality remains at 12-15%, and there is ...
Gencer, Baris, Mach, François
core   +1 more source

Compact 9dBEs Enable Efficient and Precise Genome Editing in Mammalian Cells and In Vivo

Advanced Science, EarlyView.
As a compact type II‐D system, the Cas9d‐based platform holds great potential for in vivo applications. Through rational engineering, its derived base editors (9dBEs) enable efficient disease modeling while facilitating single‐vector AAV delivery for in vivo genome editing. These miniature tools offer a robust strategy for basic research and biomedical
Qingquan Xiao, Zhijin Tian, Luqi Weng, Kun Xu, Dingyi Han, Zhaowei Wu, Junnan Li, Shangpu Li, Qijing Zhang, Xiaohui Zhao, Guoling Li, Yinghui Wei, Zhen Gu   +12 more
wiley   +1 more source